20 years and $2B later, FDA approves gene-silencing drug

01/31/2013 | New York Times (tiered subscription model), The · Xconomy

The FDA approved antisense drug Kynamro to treat homozygous familial hypercholesterolemia, a rare, inherited disorder. The technology on which the drug is based was initially developed by Gilead Sciences, which sold its patents to Isis Pharmaceuticals. Sarepta Therapeutics and Prosensa are developing gene-silencing drugs to treat muscular dystrophy.

View Full Article in:

New York Times (tiered subscription model), The · Xconomy

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA